Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patientThe unconfirmed ...
Eli Lilly Canada, Inc announced today that Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available ...
CalciMedica’s stock nosedived after the biotech abandoned a phase 2 study of its calcium release-activated calcium (CRAC) ...
Changing the mechanism of action may offer more durable disease control for patients with PsA who do not respond to an initial TNF inhibitor.
Corvus Pharmaceuticals, Inc. shares are up on solid soquelitinib AD phase 1 data: 75% hit EASI 75 at 200 mg BID, many ...
MedPage Today on MSN
Prior biologic use tied to JAK inhibitor benefit in ulcerative colitis
In certain patients, JAK inhibitor rescue medications seem to be more effective, researche ...
GlobalData on MSN
D3 Bio receives FDA clearance to advance KRAS inhibitor trials
The Phase II trial will assess the early efficacy, safety and pharmacokinetics of combining elisrasib with D3S 002.
ACE inhibitor use was associated with reduced all cause mortality in idiopathic pulmonary fibrosis in a matched real world ...
A research team has made a breakthrough in epigenetic drug discovery. The researchers have successfully developed a ...
Sources of error that may lead to false association include PPI use shortly before diagnosis, short-term PPI use.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results